This observational study is looking at whether using brain tissue collected during surgery can help predict how well different treatments might work for central nervous system (CNS) tumors. Researchers will take a small piece of your tumor tissue after it's removed and test it in the lab to see how it responds to various drugs. This approach, called patient-derived explant (PDE), aims to find the most effective therapy for each patient, as CNS tumors can be very different from person to person. The study plans to enroll 50 participants, both children and adults. The main goal is to see how many of these tissue samples can be successfully tested within 28 days.

Study design

This is an observational study with a planned enrollment of 50 participants. It is not a drug trial but focuses on collecting and testing biospecimens.

What's involved

You would provide a biospecimen (tumor tissue) during your surgery. The trial record does not specify any other visits, procedures, or tests for participants.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured up to 28 days after the biospecimen is collected.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.